The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
The House and Senate want to reduce or eliminate federal tax credits for “orphan drugs” used to treat rare diseases, but patients are fighting against the plan.
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
Following a KHN and NPR investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.